Boma B Mohammed1
,
Adamu B Isah2,
Teryilla S Allagh2,
Philip F Builders3,
For correspondence:- Boma Mohammed Email: disciplebbm@gmail.com Tel: +2348067728578
Published: 11 December 2019
Citation: Mohammed BB, Isah AB, Allagh TS, Builders PF, Effects of a co-processed novel multifunctional excipient on the tablet properties of metronidazole. J Sci Pract Pharm 2019; 6(1):316-323 doi: 10.47227/jsppharm.v6i1.6
© 2019 The author(s).
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only. .
Purpose: The objective of this work was to formulate and determine the effects of a co-processed novel, multifunctional pharmaceutical excipient on tablet parameters of metronidazole tablets produced by direct compression. Methods: The excipient was prepared by co-processing lactose, mucin and gelatin in a ratio of 90:1:9, dried and pulverized into powder using the co-fusion method. The excipient formulated was characterized using Differential scanning calorimetry (DSC) and Fourier transform infra-red spectroscopy (FTIR). The excipient was used to prepare metronidazole tablets and compared with other modified excipients like Cellactose® and Spray dried lactose®. Parameters evaluated on tablets include crushing strength, friability, disintegration, tablet assay and in-vitro studies. Results: DSC analysis revealed a crystalline excipient due to the high content of lactose in the formulation while FTIR showed no interaction between the excipient and metronidazole showing compatibility. Tablets prepared had an average weight of 0.49 g, crushing strength of 4.3 KgF, friability of 0.65 %, disintegration time of 14 min and time taken for 50 % of the drug to be released was 14 min. Conclusion: A multifunctional co-processed excipient having a filler-binder-lubricant property was prepared. The drug-excipient ratio (40:60) of the co-processed excipient gave pharmaceutically acceptable tablets that met the British Pharmacopoeia specifications as well as compared well with the modified excipients used due to improvement in the flow property as a result of co-processing.
